Hematology/Oncology policy updates
Track new and updated Hematology/Oncology policies impacting reimbursement and clinical operations.
| Policy | Payer | Type | Specialty | Change | Effective |
|---|---|---|---|---|---|
| Irreversible Electroporation (IRE) of Tumors Other Than Liver | Blue Cross Blue Shield - Rhode Island | Clinical | Hematology/Oncology | Modified | Jun 1, 2026 |
| Minimal Residual Disease (MRD) Testing for Cancer | Blue Cross Blue Shield - Rhode Island | Clinical | Hematology/Oncology | Modified | Apr 1, 2025 |
| Gene Expression Profiling for Cutaneous Melanoma | Blue Cross Blue Shield - Rhode Island | Clinical | Hematology/Oncology | Modified | Jan 11, 2025 |
| Minimal Residual Disease (MRD) Testing for Cancer - Coverage Criteria | Blue Cross Blue Shield - Rhode Island | Clinical | Hematology/Oncology | Modified | Jan 11, 2025 |
| In vitro Chemosensitivity and Chemoresistance Assays — Coverage Criteria | Blue Cross Blue Shield - Rhode Island | Clinical | Hematology/Oncology | Modified | Jan 1, 2022 |
| Chimeric Antigen Receptor (CAR) T‑cell therapy for cancer — BlueCHiP for Medicare | Blue Cross Blue Shield - Rhode Island | Clinical | Hematology/Oncology | Modified | Aug 7, 2019 |
| CAR T-cell therapy (autologous) — Coverage and CMS claims submission | Blue Cross Blue Shield - Rhode Island | Clinical | Hematology/Oncology | Modified | Aug 7, 2019 |
| Circulating Tumor DNA and Circulating Tumor Cells for Cancer Management (Liquid Biopsy) | Blue Cross Blue Shield - Rhode Island | Clinical | Hematology/Oncology | Modified | Jan 12, 2016 |
| In vitro chemosensitivity and chemoresistance assays — Coverage Criteria | Blue Cross Blue Shield - Rhode Island | Clinical | Hematology/Oncology | Modified | Apr 9, 2007 |
| Chemoresistance and Chemosensitivity Assays | Blue Cross Blue Shield - Rhode Island | Clinical | Hematology/Oncology | Modified | — |
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.
OpenPayer by Trek Health — Policy intelligence for billing and revenue cycle teams.
Coverage data is sourced from publicly available payer medical policy documents and updated as payers publish revisions. Read more about where our data comes from. Always consult the primary payer source for clinical decision-making.